Last reviewed · How we verify

NCT07047482

Clinicopathological Value of p16 Expression in Colorectal Carcinoma

Recruiting now Last updated 10 July 2025
What this trial tests

trial testing Immunohistochemical staining in Colorectal Carcinoma in 50 participants. Currently enrolling.

Timeline
1 May 2025
Primary endpoint
21 March 2026
30 December 2026

Quick facts

Lead sponsorSohag University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment50
Start date1 May 2025
Primary completion21 March 2026
Estimated completion30 December 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Sohag University

Who can join

Eligibility, any sex, with Colorectal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of the immunohistochemical expression of p16 in colorectal carcinoma and correlate its expression to different clinical and pathological parameters as patients' ages, sexes, tumor location, histopathological phenotype, status of nodal involvement, perineural and lymphovascular invasion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Immunohistochemical staining

Trials testing the same drug.

Other recruiting trials for Colorectal Carcinoma

Currently open trials in the same condition.

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07047482.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing